Lymphedema is mainly identified by progressive soft tissue swelling in impaired lymphatic system. Secondary lymphedema attributed to cancer therapy, parasite infection, and trauma remains a serious global disease. Patients with lymphedema suffer swelling, pain, and fatigue, with the dysfunction of the deformed extremities reducing the quality of life and increasing the risk of infection and lymphangiosarcoma. Adipose-derived stem cells (ADSCs) possess prominent regenerative potential to differentiate into multilineage cells, and produce various lymphangiogenic factors, making ADSC therapy a promising approach for lymphedema. The development of lymphedema consists of local inflammation, the fibrosis of lymphatic vessels, and the deposition of adipose fat. Existing animal models do not mimic the chronic inflammation environment, therefore suitable models are required in further studies. Some signal pathways and molecular mechanisms in physiological and pathological lymphagiogenesis remain unclear. In previous animal and human trials, ADSC therapy reduced edema in varying degrees. A larger number of trials with larger samples and longer follow-up periods are required to verify the efficiency and feasibility of ADSC therapy. ADSCs are of easy availability and immune exemption, making them a candidate for lymphedema treatment. Whether ADSCs enhance malignant characteristics or trigger the malignant change deserves further exploration and study before ADSC therapy can be made widely available.

中文翻译：

---

脂肪干细胞疗法对继发性淋巴水肿显示出令人鼓舞的结果。

淋巴水肿主要由淋巴系统受损引起的进行性软组织肿胀所鉴定。归因于癌症治疗，寄生虫感染和创伤的继发性淋巴水肿仍然是一种严重的全球性疾病。淋巴水肿的患者会肿胀，疼痛和疲劳，四肢畸形的功能障碍会降低生活质量，并增加感染和淋巴管肉瘤的风险。脂肪干细胞（ADSC）具有显着的再生潜能，可以分化为多系细胞，并产生多种淋巴管生成因子，这使ADSC治疗成为一种有希望的淋巴水肿治疗方法。淋巴水肿的发展包括局部炎症，淋巴管纤维化和脂肪沉积。现有的动物模型无法模仿慢性炎症环境，因此，在进一步研究中需要合适的模型。生理和病理性淋巴血管生成中的某些信号途径和分子机制仍不清楚。在先前的动物和人体试验中，ADSC治疗可不同程度地减轻水肿。为了验证ADSC治疗的有效性和可行性，需要进行大量具有较大样本和更长随访时间的试验。ADSC具有容易获得和免疫豁免的特性，使其成为淋巴水肿治疗的候选药物。ADSC是增强恶性特征还是引发恶性变化，在可以广泛使用ADSC治疗之前，还需要进一步探索和研究。在先前的动物和人体试验中，ADSC治疗可不同程度地减轻水肿。为了验证ADSC治疗的有效性和可行性，需要进行大量具有较大样本和更长随访时间的试验。ADSC具有容易获得和免疫豁免的特性，使其成为淋巴水肿治疗的候选药物。ADSC是增强恶性特征还是引发恶性变化，在可以广泛使用ADSC治疗之前，还需要进一步探索和研究。在先前的动物和人体试验中，ADSC治疗可不同程度地减轻水肿。为了验证ADSC治疗的有效性和可行性，需要进行更多的具有较大样本量和更长随访时间的试验。ADSC具有容易获得和免疫豁免的特性，使其成为淋巴水肿治疗的候选药物。ADSC是增强恶性特征还是引发恶性变化，在可以广泛使用ADSC治疗之前，还需要进一步探索和研究。